John Libbey Eurotext

European Journal of Dermatology

A case of a focal oedematous reaction induced by rituximab overlying lupus erythematosus tumidus Volume 27, issue 5, September-October 2017

Figures

  • Figure 1
Authors
1 Department of Dermatology,
Avicenne Hospital,
Assistance Publique des Hôpitaux de Paris (AP-HP),
University Paris 13,
93000 Bobigny,
France
2 Department of Pathology,
Avicenne Hospital,
AP-HP,
93000 Bobigny,
France

Rituximab, a chimeric murine/human monoclonal antibody directed against CD20, has been used off-label to treat systemic lupus erythematosus (SLE) and may be effective against refractory chronic cutaneous lupus erythematosus (CCLE) [1]). Focal rituximab-related urticarial/oedematous reactions have been reported in several patients treated for primary cutaneous B-cell lymphoma (PCBL). We report a patient with an immediate oedematous reaction to rituximab involving tumidus CCLE plaques.In 2010, a 50-year-old [...]